The findings indicate that I3C significantly (p < 0.05) downregulated IL-10 and IL-17 levels compared to OVA treatment, indicating that I3C helps regulate the balanced pathway of Th17/Treg cells to alleviate asthma’s inflammatory symptoms. This evidence concerns the gene IL17A and asthma.